KR20240082408A - 인자 viii 키메라 단백질의 제형 및 이의 용도 - Google Patents
인자 viii 키메라 단백질의 제형 및 이의 용도 Download PDFInfo
- Publication number
- KR20240082408A KR20240082408A KR1020247015817A KR20247015817A KR20240082408A KR 20240082408 A KR20240082408 A KR 20240082408A KR 1020247015817 A KR1020247015817 A KR 1020247015817A KR 20247015817 A KR20247015817 A KR 20247015817A KR 20240082408 A KR20240082408 A KR 20240082408A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- arginine
- sucrose
- poloxamer
- histidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256432P | 2021-10-15 | 2021-10-15 | |
| US63/256,432 | 2021-10-15 | ||
| PCT/US2022/078097 WO2023064886A1 (en) | 2021-10-15 | 2022-10-14 | Formulations of factor viii chimeric proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240082408A true KR20240082408A (ko) | 2024-06-10 |
Family
ID=84362012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247015817A Pending KR20240082408A (ko) | 2021-10-15 | 2022-10-14 | 인자 viii 키메라 단백질의 제형 및 이의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240358800A1 (enExample) |
| EP (1) | EP4415693B1 (enExample) |
| JP (1) | JP2024538091A (enExample) |
| KR (1) | KR20240082408A (enExample) |
| CN (1) | CN118103034A (enExample) |
| AU (1) | AU2022366974A1 (enExample) |
| CA (1) | CA3229979A1 (enExample) |
| CO (1) | CO2024004211A2 (enExample) |
| IL (1) | IL311969A (enExample) |
| MX (1) | MX2024004494A (enExample) |
| TW (1) | TW202334244A (enExample) |
| WO (1) | WO2023064886A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124690C (en) * | 1992-10-02 | 2007-09-11 | Thomas Osterberg | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| PL3793588T3 (pl) * | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
-
2022
- 2022-10-14 CN CN202280069172.7A patent/CN118103034A/zh active Pending
- 2022-10-14 JP JP2024522237A patent/JP2024538091A/ja active Pending
- 2022-10-14 TW TW111139016A patent/TW202334244A/zh unknown
- 2022-10-14 KR KR1020247015817A patent/KR20240082408A/ko active Pending
- 2022-10-14 EP EP22813008.4A patent/EP4415693B1/en active Active
- 2022-10-14 WO PCT/US2022/078097 patent/WO2023064886A1/en not_active Ceased
- 2022-10-14 CA CA3229979A patent/CA3229979A1/en active Pending
- 2022-10-14 AU AU2022366974A patent/AU2022366974A1/en active Pending
- 2022-10-14 MX MX2024004494A patent/MX2024004494A/es unknown
- 2022-10-14 IL IL311969A patent/IL311969A/en unknown
-
2024
- 2024-04-04 CO CONC2024/0004211A patent/CO2024004211A2/es unknown
- 2024-04-10 US US18/632,038 patent/US20240358800A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4415693A1 (en) | 2024-08-21 |
| JP2024538091A (ja) | 2024-10-18 |
| MX2024004494A (es) | 2024-07-15 |
| CA3229979A1 (en) | 2023-04-20 |
| CN118103034A (zh) | 2024-05-28 |
| EP4415693C0 (en) | 2026-02-18 |
| EP4415693B1 (en) | 2026-02-18 |
| US20240358800A1 (en) | 2024-10-31 |
| CO2024004211A2 (es) | 2024-04-18 |
| TW202334244A (zh) | 2023-09-01 |
| WO2023064886A1 (en) | 2023-04-20 |
| AU2022366974A1 (en) | 2024-05-30 |
| IL311969A (en) | 2024-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11510968B2 (en) | Method for improving the stability of purified Factor VIII after reconstitution | |
| JP6250282B2 (ja) | 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子 | |
| JP5784907B2 (ja) | 組換え型vwf製剤 | |
| JP7741145B2 (ja) | 第ix因子ポリペプチド製剤 | |
| TWI670072B (zh) | 凍乾的重組vwf調配物 | |
| WO1995016460A1 (en) | Composition containing soluble thrombomodulins | |
| KR20170026580A (ko) | 변형된 폰 빌레브란트 인자 | |
| RU2426745C2 (ru) | Рекомбинантный химерный белок фактора ингибирования нейтрофилов и гиругена и содержащая его фармацевтическая композиция | |
| JP2023166014A (ja) | コラーゲン7組成物及びそれを用いる方法 | |
| EP4358938A1 (en) | Formulations of factor viii chimeric proteins and uses thereof | |
| EP4415693B1 (en) | Formulations of factor viii chimeric proteins and uses thereof | |
| IL154600A (en) | Pharmaceutical preparations containing an analogue of thrombomodulin for the treatment of spinal cord injuries | |
| WO2024077335A1 (en) | Factor ix variant polypeptides for administration to soft tissue | |
| KR102058864B1 (ko) | 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물 | |
| EA051115B1 (ru) | Составы на основе химерных белков, содержащих фактор viii, и варианты их применения | |
| WO2024141054A1 (zh) | 包含融合蛋白的药物组合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |